Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into an exclusive license agreement with Lexicon Pharmaceuticals (Nasdaq: LXRX) for...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced an exclusive license agreement with China-based United Laboratories International Holdings Limited and its wholly-owned...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Novo Nordisk in the transaction. IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, announced a strategic...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced expanding its collaboration with Valo Health, Inc. (Valo) in a deal worth up to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies,...
You must be a Standard 1 Year member to access this content.
King & Spalding successfully defended Novo Nordisk in a federal antitrust suit in New York alleging Novo Nordisk, along with other major insulin manufacturers, conspired to...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...
You must be a Standard 1 Year member to access this content.
